Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

Trace/s,” an exhibition at the Center for Brooklyn History, highlights the borough’s neglected story of slavery — and the Black genealogists helping to unearth it.

Eli Lilly (NYSE ... in the past three months, Lilly's valuation has declined by 21%. It fell last week after the company released updated guidance, with revenue for its GLP-1 drugs projected ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

After the family of Grayson Roberts, a 10-year-old Southern California boy who is blind due to a rare genetic eye condition, lost their home to the Eaton Fire, community members are coming together to ...

Eli Lilly said it received Food and Drug Administration ... The treatment, developed by the pharmaceutical company under the brand name Omvoh, is now approved to treat two types of inflammatory ...

The company only reported Q3 revenues of $11.44 billion, and the guidance for Q4 was a very aggressive revenue target of $13.9 billion. Eli Lilly only reached revenues of $13.5 billion ...

Eli Lilly forecasts $45 billion in 2024 revenue ... Get the Real Story Behind Every Major Earnings Report The company's expected 2024 revenue is $400 million, or about 3%, below the guidance ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...

Eli Lilly and Company (NYSE:LLY) shares slid 6.6% to $744.91, after it said it expects Q4 revenue at $13.5 billion- weaker than street expectations of $14.08 billion. The miss was driven largely ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In one of his latest appearances on CNBC's Squawk on the Street, Jim Cramer ...